• Something wrong with this record ?

Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter

D. Vagiannis, Y. Zhang, Y. Budagaga, E. Novotna, A. Skarka, S. Kammerer, JH. Küpper, J. Hofman

. 2022 ; 434 (-) : 115823. [pub] 20211209

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22011599

Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in late-phase trials for the therapy of various malignancies. In the present work, we describe alisertib's potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act as an antagonist of multidrug resistance (MDR). In accumulation assays, alisertib potently inhibited ABCC1 transporter, but not ABCB1 or ABCG2. The results of molecular modeling suggested a bifunctional mechanism for interaction on ABCC1. In addition, alisertib was characterized as a low- to moderate-affinity inhibitor of recombinant CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 isoenzymes, but without potential clinical relevance. Drug combination studies revealed the capability of alisertib to synergistically antagonize ABCC1-mediated resistance to daunorubicin. Although alisertib exhibited substrate characteristics toward ABCB1 transporter in monolayer transport assays, comparative proliferation studies showed lack of its MDR-victim behavior in cells overexpressing ABCB1 as well as ABCG2 and ABCC1. Lastly, alisertib did not affect the expression of ABCC1, ABCG2, ABCB1 transporters and CYP1A2, CYP3A4, CYP2B6 isozymes on mRNA level in various systemic and tumoral models. In conclusion, our study suggests that alisertib is a drug candidate with negligible potential for perpetrating systemic pharmacokinetic DDIs on ABCB1, ABCG2 and cytochromes P450. In addition, we introduce alisertib as an effective dual-activity chemosensitizer whose MDR-antagonistic capacities are not impaired by efflux or effect on MDR phenotype. Our in vitro findings provide important pieces of information for clinicians when introducing alisertib into the clinical area.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011599
003      
CZ-PrNML
005      
20220506130555.0
007      
ta
008      
220425s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.taap.2021.115823 $2 doi
035    __
$a (PubMed)34896433
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vagiannis, Dimitrios $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovskeho 1203, 500 05 Hradec Králové, Czech Republic
245    10
$a Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter / $c D. Vagiannis, Y. Zhang, Y. Budagaga, E. Novotna, A. Skarka, S. Kammerer, JH. Küpper, J. Hofman
520    9_
$a Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in late-phase trials for the therapy of various malignancies. In the present work, we describe alisertib's potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act as an antagonist of multidrug resistance (MDR). In accumulation assays, alisertib potently inhibited ABCC1 transporter, but not ABCB1 or ABCG2. The results of molecular modeling suggested a bifunctional mechanism for interaction on ABCC1. In addition, alisertib was characterized as a low- to moderate-affinity inhibitor of recombinant CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 isoenzymes, but without potential clinical relevance. Drug combination studies revealed the capability of alisertib to synergistically antagonize ABCC1-mediated resistance to daunorubicin. Although alisertib exhibited substrate characteristics toward ABCB1 transporter in monolayer transport assays, comparative proliferation studies showed lack of its MDR-victim behavior in cells overexpressing ABCB1 as well as ABCG2 and ABCC1. Lastly, alisertib did not affect the expression of ABCC1, ABCG2, ABCB1 transporters and CYP1A2, CYP3A4, CYP2B6 isozymes on mRNA level in various systemic and tumoral models. In conclusion, our study suggests that alisertib is a drug candidate with negligible potential for perpetrating systemic pharmacokinetic DDIs on ABCB1, ABCG2 and cytochromes P450. In addition, we introduce alisertib as an effective dual-activity chemosensitizer whose MDR-antagonistic capacities are not impaired by efflux or effect on MDR phenotype. Our in vitro findings provide important pieces of information for clinicians when introducing alisertib into the clinical area.
650    _2
$a P-glykoprotein $x genetika $x metabolismus $7 D020168
650    _2
$a ABC transportér z rodiny G, člen 2 $x genetika $x metabolismus $7 D000070997
650    _2
$a zvířata $7 D000818
650    _2
$a azepiny $x farmakokinetika $x farmakologie $7 D001381
650    _2
$a katalytická doména $7 D020134
650    _2
$a buněčné linie $7 D002460
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    _2
$a psi $7 D004285
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a lékové interakce $7 D004347
650    _2
$a regulace genové exprese $x účinky léků $7 D005786
650    _2
$a lidé $7 D006801
650    _2
$a molekulární modely $7 D008958
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a proteiny spojené s mnohočetnou rezistencí k lékům $x antagonisté a inhibitory $7 D027425
650    _2
$a konformace proteinů $7 D011487
650    _2
$a pyrimidiny $x farmakokinetika $x farmakologie $7 D011743
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zhang, Yu $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovskeho 1203, 500 05 Hradec Králové, Czech Republic
700    1_
$a Budagaga, Youssif $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovskeho 1203, 500 05 Hradec Králové, Czech Republic
700    1_
$a Novotna, Eva $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovskeho 1203, 500 05 Hradec Králové, Czech Republic
700    1_
$a Skarka, Adam $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradecká 1285, Hradec Králové 500 03, Czech Republic
700    1_
$a Kammerer, Sarah $u Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968 Senftenberg, Germany
700    1_
$a Küpper, Jan-Heiner $u Institute of Biotechnology, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz 1, 01968 Senftenberg, Germany
700    1_
$a Hofman, Jakub $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovskeho 1203, 500 05 Hradec Králové, Czech Republic. Electronic address: jakub.hofman@faf.cuni.cz
773    0_
$w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 434, č. - (2022), s. 115823
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34896433 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130547 $b ABA008
999    __
$a ok $b bmc $g 1789280 $s 1162797
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 434 $c - $d 115823 $e 20211209 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
LZP    __
$a Pubmed-20220425
Back

Find record

Citation metrics

Archiving options